<DOC>
	<DOCNO>NCT01159912</DOCNO>
	<brief_summary>A randomised , double-blind , double-dummy , placebo control ( rescue medication ) , multicenter study evaluate efficacy safety Fluticasone Furoate inhalation powder treatment persistent asthma adult adolescent .</brief_summary>
	<brief_title>Evaluating Efficacy Safety Fluticasone Furoate Inhalation Powder Treatment Asthma Adults Adolescents</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , double-dummy , parallel-group study compare efficacy safety Fluticasone Furoate Inhalation Powder 100mcg daily Fluticasone Propionate Inhalation Powder 250mcg twice daily Placebo . Subjects participate study maximum 29 week ( include screening , treatment follow-up contact ) . The primary endpoint consist change baseline clinic visit trough ( pre-bronchodilator pre-dose ) FEV1 end 24 week treatment period . The nominated powered secondary endpoint change baseline percentage rescue-free 24 hour period 24-week treatment period . Safety assessment include adverse event , oropharyngeal examination , clinical chemistry urine cortisol excretion . For subject consent pharmacogenetics , blood sample also take pharmacogenetic analysis .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Signed informed consent Outpatient least 12 year age Both gender ; female child bear potential must willing use approve birth control method Prebronchodilator FEV1 4090 % predict Reversibility FEV1 least 12 % 200mLs Current asthma therapy include inhaled corticosteroid least 4 week prior first visit History life threaten asthma Respiratory infection candidiasis Asthma exacerbation within 6 month prior first visit Concurrent respiratory disease disease would confound study participation affect subject safety Allergies study drug , study drug excipients , medication relate study drug Taking another investigational medication medication prohibit use study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>fluticasone propionate</keyword>
	<keyword>Fluticasone furoate</keyword>
</DOC>